Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9761)	12/15/2003 1:44:52 PM
From: Ian@SI	Read Replies (2) \| Respond to of 52153

But it's not clear just how much impact this news will have given the drug is already approved. Isn't that a little harsh? Surely cutting a year off of a Phase III trial will lower MLNM's costs somewhat even though it appears that treatment will continue for those who want it in both arms of the APEX trial. Can't we also conclude that the early APEX results overwhelmingly favoured Velcade? The key for Velcade at this point is showing efficacy in other solid tumors At ASH, I believe MLNM said that first solid tumour results should be released to the public at ASCO. So it would seem that we will have almost another 7 months of waiting ...